M1774

Phase 2Small molecule

EMD Serono Research & Development Institute, Inc.

M1774 is one of 104 small molecule programs targeting Metastatic or Locally Advanced Unresectable Solid Tumors. It is currently in Phase 2.

Indications

Total Trials

Active Trials

103

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic or Locally Advanced Unresectable Solid TumorsActive, not recruiting

Non-Squamous NSCLCActive, not recruiting

Endometrial CancerRecruiting

Breast CancerNot yet recruiting

Metastatic or Locally Advanced Unresectable Solid TumorsPhase 1

Active, not recruiting

Non-Squamous NSCLCPreclinical

Active, not recruiting

Endometrial CancerPhase 2

Recruiting

Breast CancerPhase 2

Not yet recruiting

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

M1774

EMD Serono Research & Development Institute, Inc.

Phase 2

1 2

Adenocard

Astellas

Preclinical

2 3

Lexiscan

Astellas

Preclinical

1 4

Voltaren

Novartis

Preclinical

1 5

Zolymbus

AbbVie

Preclinical

1 6

Blenoxane

Bristol-Myers Squibb

Preclinical

1 7

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 8

Duragesic-100

CCephalon

Preclinical

2 9

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

2 10

Spravato

WWim Janssens

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Metastatic or Locally Advanced Unresectable Solid Tumors

NCT04170153

Q4 2027

Phase 1/2Not yet recruiting

Breast Cancer

NCT05986071

Q3 2029

Phase 2Recruiting

Endometrial Cancer

NCT06518564

Clinical

Trials by Indication[1]

Endometrial Cancer1 trial

Avelumab and M1774 in ARID1A-mutated Endometrial Cancer

Recruiting·—·Phase 2·NCT06518564·25 enrolled

Breast Cancer1 trial

I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers

Not yet recruiting·IInstitut Paoli-Calmettes·Phase 1/2·NCT05986071·57 enrolled

Non-Small Cell Lung Cancer1 trial

An Open Label, Multicenter, Phase 1b/2a Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of the ATR Inhibitor M1774 in Combination With Cemiplimab in Participants With Non-Squamous Non-Small Cell Lung Cancer That Has Progressed on Prior Anti-PD-(L)1 and Platinum-based Therapies (DDRiver NSCLC 322)

Completed· EMD Serono Research & Development Institute, Inc. logo

EMD Serono Research & Development Institute, Inc.·Preclinical·NCT05882734·61 enrolled

Metastatic or Locally Advanced Unresectable Solid Tumors1 trial

An Open-label, Multicenter Trial of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)

Active, not recruiting· EMD Serono Research & Development Institute, Inc. logo

EMD Serono Research & Development Institute, Inc.·Phase 1·NCT04170153·161 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for M1774. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — M1774 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for M1774. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — EMD Serono Research & Development Institute, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: EMD Serono Research & Development Institute, Inc.

M1774

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2027

Q3 2029

Trials by Indication[1]

Endometrial Cancer1 trial

Breast Cancer1 trial

Non-Small Cell Lung Cancer1 trial

Metastatic or Locally Advanced Unresectable Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News